[go: up one dir, main page]

DK3071595T3 - Humaniseret anti-kallikrein-2-antistof - Google Patents

Humaniseret anti-kallikrein-2-antistof Download PDF

Info

Publication number
DK3071595T3
DK3071595T3 DK14814696.2T DK14814696T DK3071595T3 DK 3071595 T3 DK3071595 T3 DK 3071595T3 DK 14814696 T DK14814696 T DK 14814696T DK 3071595 T3 DK3071595 T3 DK 3071595T3
Authority
DK
Denmark
Prior art keywords
callicine
antibody
humanized anti
humanized
Prior art date
Application number
DK14814696.2T
Other languages
English (en)
Inventor
Sven-Erik Strand
Urpo Juhani Lamminmäki
Kjell Sjöström
Pär Oskar Vilhelmsson Timmermand
Amanda Thuy Tran
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Application granted granted Critical
Publication of DK3071595T3 publication Critical patent/DK3071595T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
DK14814696.2T 2013-11-19 2014-11-19 Humaniseret anti-kallikrein-2-antistof DK3071595T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody

Publications (1)

Publication Number Publication Date
DK3071595T3 true DK3071595T3 (da) 2019-07-01

Family

ID=52114029

Family Applications (1)

Application Number Title Priority Date Filing Date
DK14814696.2T DK3071595T3 (da) 2013-11-19 2014-11-19 Humaniseret anti-kallikrein-2-antistof

Country Status (23)

Country Link
US (3) US10100125B2 (da)
EP (2) EP3071595B1 (da)
JP (4) JP6599859B2 (da)
KR (2) KR102574537B1 (da)
CN (2) CN105980404B (da)
AU (3) AU2014351611B2 (da)
BR (1) BR112016011025B1 (da)
CA (1) CA2930493A1 (da)
CY (1) CY1121900T1 (da)
DK (1) DK3071595T3 (da)
ES (1) ES2728515T3 (da)
HR (1) HRP20191095T1 (da)
HU (1) HUE043875T2 (da)
IL (5) IL297678B2 (da)
LT (1) LT3071595T (da)
MX (2) MX383543B (da)
PL (1) PL3071595T3 (da)
PT (1) PT3071595T (da)
RS (1) RS58831B1 (da)
RU (1) RU2687163C1 (da)
SI (1) SI3071595T1 (da)
SM (1) SMT201900338T1 (da)
WO (1) WO2015075445A1 (da)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX353964B (es) 2011-10-28 2018-02-06 Fredax Ab Agentes terapeuticos y usos de los mismos.
EA036387B1 (ru) 2012-03-05 2020-11-03 Ой Арктик Партнерс Аб Способы и аппараты для прогнозирования риска рака предстательной железы и объема предстательной железы
MX383543B (es) * 2013-11-19 2025-03-14 Janssen Biotech Inc Anticuerpo anti-calicreina-2 humanizado.
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
US11761962B2 (en) 2014-03-28 2023-09-19 Opko Diagnostics, Llc Compositions and methods related to diagnosis of prostate cancer
PL3253800T3 (pl) 2015-03-27 2021-08-23 Opko Diagnostics, Llc Standardy antygenów prostaty i ich zastosowanie
EP3377117A1 (en) * 2015-11-18 2018-09-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
CN110234661B (zh) 2016-12-01 2024-03-29 瑞泽恩制药公司 用于免疫pet成像的放射性标记的抗-pd-l1抗体
IL268667B2 (en) 2017-02-10 2024-12-01 Regeneron Pharma Radiolabeled antibodies against LAG3 for immuno-PET imaging
CN110945025B (zh) 2017-03-30 2023-11-03 Ecs前胃泌素股份有限公司 用于检测前列腺癌的组合物和方法
WO2019023148A1 (en) 2017-07-24 2019-01-31 Regeneron Pharmaceuticals, Inc. ANTI-CD8 ANTIBODIES AND USES THEREOF
BR112021022237A2 (pt) 2019-05-10 2022-03-29 Janssen Biotech Inc Queladores macrocíclicos e métodos de uso dos mesmos
CN118515779A (zh) 2019-07-26 2024-08-20 詹森生物科技公司 抗hk2嵌合抗原受体（car）
PE20220649A1 (es) 2019-07-26 2022-04-28 Janssen Biotech Inc Proteinas que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos
CR20220594A (es) 2020-05-27 2023-01-17 Janssen Biotech Inc Proteins comprising cd3 antigen binding domains and uses thereof
EP4182353A1 (en) 2020-07-17 2023-05-24 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
CN116615194A (zh) * 2020-11-10 2023-08-18 詹森生物科技公司 大环化合物及其使用方法
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
WO2022156798A1 (zh) * 2021-01-25 2022-07-28 成都康弘生物科技有限公司 一种抗体及其用途
WO2022162549A2 (en) 2021-01-27 2022-08-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
EP4284839A4 (en) * 2021-01-28 2025-04-23 Astria Therapeutics, Inc. Plasma kallikrein antibodies and uses thereof
WO2022249089A1 (en) * 2021-05-27 2022-12-01 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
WO2023084397A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
EP4469095A1 (en) 2022-01-26 2024-12-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
JP2001503991A (ja) 1996-11-14 2001-03-27 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチ 転移性前立腺癌の検出方法
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
AU3879200A (en) 1999-08-16 2001-03-13 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
IL158969A0 (en) 2001-06-01 2004-05-12 Cornell Res Foundation Inc Modified antibodies to prostate-specific membrane antigen and uses thereof
US7514078B2 (en) * 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
WO2003080672A1 (en) 2002-03-22 2003-10-02 Aprogen, Inc. Humanized antibody and process for preparing same
AU2004209984B2 (en) 2003-01-31 2010-08-05 Albor Biologics, Inc. Immune regulation based on the targeting of early activation molecules
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
CN101094869A (zh) * 2004-08-03 2007-12-26 戴埃克斯有限公司 Hk1结合蛋白
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
EP1851251A2 (en) * 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
KR20150067395A (ko) 2006-12-01 2015-06-17 메다렉스, 엘.엘.시. 씨디22에 결합하는 인간 항체 및 이의 용도
RU2502074C2 (ru) * 2006-12-22 2013-12-20 Фадиа Аб Новый аллерген-простатический калликреин
WO2010045340A1 (en) 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
MX353964B (es) * 2011-10-28 2018-02-06 Fredax Ab Agentes terapeuticos y usos de los mismos.
MX383543B (es) * 2013-11-19 2025-03-14 Janssen Biotech Inc Anticuerpo anti-calicreina-2 humanizado.
WO2023278463A1 (en) 2021-06-29 2023-01-05 Volastra Therapeutics, Inc. Anti-enpp1 antibodies and uses thereof

Also Published As

Publication number Publication date
JP2025019101A (ja) 2025-02-06
EP3071595A1 (en) 2016-09-28
JP2020022470A (ja) 2020-02-13
EP3553088A1 (en) 2019-10-16
MX2016006561A (es) 2016-12-12
BR112016011025B1 (pt) 2024-01-23
IL245617B (en) 2021-02-28
RU2016124229A (ru) 2017-12-25
ES2728515T3 (es) 2019-10-25
PT3071595T (pt) 2019-06-11
KR20220020406A (ko) 2022-02-18
WO2015075445A1 (en) 2015-05-28
CN105980404A (zh) 2016-09-28
US20190169312A1 (en) 2019-06-06
MX383543B (es) 2025-03-14
IL311788A (en) 2024-05-01
HRP20191095T1 (hr) 2019-09-20
IL297678A (en) 2022-12-01
IL297678B2 (en) 2024-09-01
CY1121900T1 (el) 2020-10-14
MX2021007006A (es) 2021-09-08
JP2016540503A (ja) 2016-12-28
JP7051777B2 (ja) 2022-04-11
BR112016011025A2 (pt) 2017-12-05
IL323633A (en) 2025-11-01
BR112016011025A8 (pt) 2018-01-30
PL3071595T3 (pl) 2019-09-30
IL297678B1 (en) 2024-05-01
SMT201900338T1 (it) 2019-07-11
RS58831B1 (sr) 2019-07-31
IL311788B1 (en) 2025-11-01
KR20160096621A (ko) 2016-08-16
RU2687163C1 (ru) 2019-05-07
AU2020207775A1 (en) 2020-08-06
US20220064333A1 (en) 2022-03-03
CN105980404B (zh) 2021-01-12
US20160369009A1 (en) 2016-12-22
US11230609B2 (en) 2022-01-25
LT3071595T (lt) 2019-05-10
US10100125B2 (en) 2018-10-16
IL245617A0 (en) 2016-06-30
EP3071595B1 (en) 2019-03-20
KR102574537B1 (ko) 2023-09-06
AU2014351611A1 (en) 2016-06-30
US12404343B2 (en) 2025-09-02
JP7592654B2 (ja) 2024-12-02
KR102442738B1 (ko) 2022-09-15
CN112898431A (zh) 2021-06-04
JP2022062048A (ja) 2022-04-19
JP6599859B2 (ja) 2019-10-30
CN112898431B (zh) 2024-05-28
KR20230132599A (ko) 2023-09-15
HUE043875T2 (hu) 2019-09-30
AU2020207775B2 (en) 2023-06-15
IL278493B2 (en) 2023-04-01
AU2014351611B2 (en) 2020-04-23
AU2023222879A1 (en) 2023-09-14
IL278493A (en) 2022-12-01
CA2930493A1 (en) 2015-05-28
SI3071595T1 (sl) 2019-08-30

Similar Documents

Publication Publication Date Title
IL281485B (en) Tracked all-terrain vehicle
CY2023021I2 (el) Αντισωματα που δεσμευουν την il-23
DK3071595T3 (da) Humaniseret anti-kallikrein-2-antistof
DK3336106T3 (da) Anti-fcrh5-antistoffer
DK3708583T3 (da) Ikke-fucosylerede anti-fgfr2iiib-antistoffer
IL246287B (en) Fabs-in-tandem immunoglobulin and uses thereof
ME03675B (me) Humanizovana ili himerna anтi-cd3 antiтela
LT3049441T (lt) Anti-pdl1 antikūnų kompozicija
EP3083682C0 (en) DOUBLE SPECIFICITY ANTIBODIES
PT3088419T (pt) Conjugado de anticorpo anti-trop2-fármaco
BR112014024769A2 (pt) anticorpo humanizado tau
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
DK2881868T3 (da) Søgegrænseflade
HRP20181478T1 (hr) Humanizirani anti-cd134 (ox40) protutijela i njihove uporabe
EP3070168C0 (en) ANTIGEN-BINDING MOLECULE CONTAINING MODIFIED ANTIBODY VARIABLE REGION
KR20180085002A (ko) 인간화된 항-cll-1 항체
DK3068800T3 (da) FcRn-specifikke antistoffer
BR112014025037A2 (pt) anticorpo ou um fragmento funcional do mesmo, nucleotídeo, vetor recombinante, célula, métodos para a produção de um anticorpo ou fragmento funcional, para detecção ou ensaio de fgfr2 humano iiib, para a identificação de um indivíduo receptor de uma composição farmacêutica, e, para identificar e para produzir uma substância, forma modificada, composição, e, reagente
DK3038643T3 (da) Antistoffer mod csf-1r
IL240753B (en) Methods for purifying antibodies
PL3971212T3 (pl) Białka wiążące antygen receptora onkostatyny m
ME03094B (me) Protutijela protiv kemokina pan-elr+ схс
GB201300706D0 (en) Antibody
HRP20190085T1 (hr) Anti-cd52 protutijela
DK3047163T3 (da) Lukkeelement